Compare PEBO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | OMER |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | United States |
| Employees | N/A | 175 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2005 | 2008 |
| Metric | PEBO | OMER |
|---|---|---|
| Price | $38.31 | $16.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $42.50 | $27.50 |
| AVG Volume (30 Days) | 427.5K | ★ 1.0M |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 1.59 | 0.77 |
| Revenue | $197,000.00 | ★ $29,868,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $56.09 | $73.59 |
| P/E Ratio | $23.99 | ★ $21.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.01 | $6.24 |
| 52 Week High | $42.29 | $21.24 |
| Indicator | PEBO | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 40.16 |
| Support Level | $37.53 | $16.17 |
| Resistance Level | $39.33 | $19.81 |
| Average True Range (ATR) | 0.71 | 0.81 |
| MACD | 0.30 | -0.33 |
| Stochastic Oscillator | 93.79 | 17.18 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.